THE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality

Article content

Issued on behalf of Oncolytics Biotech Inc.

Article content

VANCOUVER, British Columbia, Dec. 06, 2025 (GLOBE NEWSWIRE) — USANewsGroup.com
Market Intelligence Brief – The market is efficient… until it isn’t. While the S&P 500 grinds higher on momentum, entire subsectors have been left behind, creating a massive disconnect between Operational Reality and Stock Price.

Article content

Article content

Article content

They are quietly rotating into specific, overlooked pockets of value, from late-stage biotech to critical defense infrastructure, where the fundamentals have improved, but the valuation has not. We have identified five high-conviction anomalies.

Article content

Article content

These are companies sitting at the intersection of imminent catalysts and historical undervaluation. Let’s look at the data.

Article content

The Patent Cliff and the Universal Primer

Article content

Oncolytics Biotech (NASDAQ: ONCY) has spent two decades engineering a solution to one of oncology’s most stubborn problems. Most cancer immunotherapies fail because tumors are “cold.” The immune system cannot see them.

Article content

The company’s lead asset, pelareorep, functions as a universal primer. It converts cold tumors into hot ones, making existing blockbuster drugs effective in resistant populations.

Article content

Big Pharma is watching. The industry faces a patent cliff through 2030, with over $250 billion in annual sales at risk. Extending the life of existing franchises is now the priority. Oncolytics offers exactly that extension.

Article content

On December 1, the company announced alignment with the FDA on its pivotal Phase 3 trial design for first-line pancreatic cancer. The study will combine pelareorep with chemotherapy in a 440-patient, randomized, global trial. Primary endpoint is overall survival.

Article content

Article content

The regulatory risk is largely behind the company. Site activation is imminent. Enrollment timelines are compressed given the indication.

Article content

Phase 2 data showed a near-doubling of median overall survival compared to historical controls. The result attracted partnerships with Pfizer, Merck, and Roche across multiple indications.

Article content

The market capitalization sits below $150 million. Comparable oncology assets at this stage trade at multiples of that figure. The valuation gap reflects momentum exhaustion, not trial risk. The disconnect will narrow as enrollment progresses.

Article content

Article content

The AI Walled Garden

Article content

Avant Technologies (OTCQB: AVAI) is solving the single biggest constraint in pharmaceutical AI. The question is simple: where do you put the data?

Article content

Public models like ChatGPT are built on shared infrastructure. Every query, every dataset, every prompt passes through servers that multiple entities access. For consumer applications, this is fine. For biotech companies holding proprietary genomic sequences and clinical trial data, it is existential risk.

Article content

The liability is not theoretical. A single data breach can expose years of R&D and invite patent challenges. Pharmaceutical companies cannot use open AI systems, no matter how powerful they are.

Article content

Avant is building the alternative. The company deploys private compute grids designed for clients who need both speed and containment. The infrastructure operates as a walled garden. Data never touches public servers.

Article content

On September 25, the company announced a Pivotal Evolution of its business model. The new strategy targets high-value partnerships with biotech firms developing cell-based therapies. These companies require massive computational horsepower to model molecular interactions and optimize treatment protocols.

Article content

The timing aligns with adoption curves. Biotech is now deploying AI across drug discovery, clinical trial design, and patient stratification. The compute layer must be secure. Avant provides exactly that.

Article content

The market currently prices AVAI as a generic microcap tech stock. The classification is incorrect. This is specialized infrastructure for the most data-sensitive vertical in the economy. The company trades below $10 million in market capitalization. Comparable private cloud plays carry valuations an order of magnitude higher.

Article content

Article content

The discount reflects liquidity and awareness, not capability. As partnership announcements emerge, the rerating will follow.

Article content

Article content

The Autonomous Shield

Article content

VisionWave Holdings (NASDAQ: VWAV) provides the optical layer for modern defense networks. The company builds AI-powered detection systems designed to identify and track autonomous drone swarms in real time.

Article content

The economics of warfare have shifted. Now $500-700 drones are taking out multi-million-dollar assets (tanks, radars etc.). Legacy missile-based countermeasures are too expensive to deploy against disposable threats. The defense industry needs detection systems that are faster and cheaper than kinetic solutions.

Article content

VisionWave’s technology functions as the visual cortex for autonomous defense. The AI identifies threats before human operators can react. The speed differential is the product.

Article content

On December 2, the company unveiled Argus, a space-enabled counter-drone system developed in partnership with BladeRanger. The platform uses satellite-based optical sensors combined with AI object recognition to detect and track threats from orbit.

Article content

Article content

The strategic advantage is altitude. Ground-based radar systems are limited by line of sight and terrain. Space-based detection eliminates those constraints. Argus provides a defensive perimeter that extends beyond traditional kill zones.

Article content

The Pentagon has explicitly prioritized counter-drone technology in recent procurement cycles. Budget allocation is shifting toward autonomous systems. VisionWave sits at the center of that reallocation.

Article content

The market treats VWAV as a small-cap defense contractor. The reality is a software company embedded in hardware. The AI models are the asset. The cameras are simply the interface.

Article content

The company trades at a fraction of comparable defense technology multiples. The discount reflects limited coverage and category confusion. As Argus moves from development to deployment, the valuation gap will narrow. The trajectory is clear.

Article content

Article content

The Real Asset Refuge

Article content

GoldHaven Resources (CSE: GOH) (OTCQB: GHVNF) operates at the intersection of geopolitical risk and portfolio defense. The company is advancing a high-grade gold project in Brazil’s Juruena Province, one of the most prolific gold belts in South America.

Article content

The macro backdrop is accelerating demand. Central banks are accumulating gold at the fastest pace in decades. Inflation remains structurally embedded. Geopolitical tensions are expanding, not contracting. Real assets are no longer optional portfolio components.

Article content

GoldHaven is not a safe haven trade. It is a discovery trade. The company is drilling high-priority targets with the potential to define a significant resource.

Article content

On November 12, the company completed its first drill hole at the Western Target of its Copeçal Project. The hole intercepted a thick saprolite horizon, confirming the geologic model and validating the targeting methodology.

Article content

The Western Target sits within a structural corridor that has produced multiple gold deposits in the region. The geology is favorable. The grade potential is high. The transition from anomaly to discovery is where exploration alpha is generated.

Article content

Article content

GoldHaven trades at a steep discount to peers with comparable land positions and drill programs. The market is pricing in exploration risk without accounting for jurisdictional advantage or geologic prospectivity.

Article content

As drill results emerge and the resource footprint expands, the valuation compression will reverse. The company is advancing through the most critical phase of the exploration cycle. The inflection point is measured in quarters, not years.

Article content

Article content

The Cardiac Efficiency Engine

Article content

VentriPoint Diagnostics (TSXV: VPT) (OTCQB: VPTDF) is solving the capital expenditure crisis in cardiac imaging. Hospitals face multi-year backlogs for heart diagnostics, but they cannot afford $3 million MRI machines to clear the queue.

Article content

The company’s VMS+ software provides an alternative. The platform uses AI to transform standard 2D ultrasound images into 3D reconstructions with MRI-equivalent diagnostic accuracy. Hospitals do not need new hardware. They upgrade the machines they already own.

Article content

Article content

The economic advantage is decisive. A single MRI installation costs millions and requires specialized infrastructure. VMS+ runs on existing ultrasound equipment at a fraction of the capital outlay. The diagnostic quality is comparable. The cost structure is not.

Article content

On October 29, the company announced a strategic collaboration with Providence Health Care Ventures to validate the platform at St. Paul’s Hospital in Vancouver. The partnership provides real-world clinical data and establishes a reference site for broader hospital system adoption.

Article content

The comparable is HeartFlow, a cardiac imaging company that achieved a multi-billion dollar valuation by providing 3D coronary analysis. VentriPoint offers similar diagnostic utility without the radiation exposure or infrastructure requirements. The technology is fundamentally simpler to deploy.

Article content

The market is underpricing the infrastructure upgrade thesis. Healthcare systems globally are shifting from capital-intensive hardware purchases to software-driven efficiency gains. VentriPoint sits at the center of that transition.

Article content

The company trades below $20 million in market capitalization. The addressable market for cardiac imaging software exceeds $5 billion annually. As hospital adoption accelerates and clinical validation expands, the valuation compression will reverse. The inflection is near.

Article content

Article content

CONTACT:

Article content

Article content

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. We have also been paid fee’s from Avant Technologies, GoldHaven Resources, VisionWave Technologies, and Ventripoint Diagnostics. Again, any compensation constitutes a conflict of interest as to our ability to remain objective, so please take that into consideration when reviewing this article. The owner/operator of MIQ either own shares of the profiled companies in this publication or plan to buy and sell shares in all companies named in this publication, therefore we reserve the right to do so, no further notice will be given. We also expect further compensation as an ongoing digital media effort to increase visibility for the companies mentioned herein. Regarding Avant Technologies, GoldHaven Resources, VisionWave Technologies, and Ventripoint Diagnostics, while the technical information contained herein is derived from official regulatory filings and news releases previously approved by the issuers’ designated Qualified Persons, this specific publication has not been independently reviewed, verified, or approved by those issuers. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Article content

Article content

Article content

Article content

Article content

Article content

Article content